CY1108234T1 - Αντι-μυκητικα εμβολια βασιζομενα σε βητα-γλυκανη - Google Patents

Αντι-μυκητικα εμβολια βασιζομενα σε βητα-γλυκανη

Info

Publication number
CY1108234T1
CY1108234T1 CY20081100809T CY081100809T CY1108234T1 CY 1108234 T1 CY1108234 T1 CY 1108234T1 CY 20081100809 T CY20081100809 T CY 20081100809T CY 081100809 T CY081100809 T CY 081100809T CY 1108234 T1 CY1108234 T1 CY 1108234T1
Authority
CY
Cyprus
Prior art keywords
glucan
antibodies
protective
presented
glycan
Prior art date
Application number
CY20081100809T
Other languages
English (en)
Inventor
Luciano Polonelli
Antonio Cassone
Original Assignee
Luciano Polonelli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luciano Polonelli filed Critical Luciano Polonelli
Publication of CY1108234T1 publication Critical patent/CY1108234T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Αντισώματα αντι-γλυκάνης έχουν βρεθεί ότι είναι προστατευτικά έναντι συστημικής μυκητικής μόλυνσης με C. albicans, αλλά η προστατευτική αποτελεσματικότητα μπορεί να ανασταλλεί από παρακωλυτικά αντισώματα. Η εφεύρεση παρέχει μία ανοσογόνο σύνθεση η οποία περιλαμβάνει μία γλυκάνη και έναν φαρμακευτικά αποδεκτό φορέα και χαρακτηρίζεται από το ότι, όταν χορηγείται σε έναν αποδέκτη θηλαστικό η σύνθεση προκαλεί προστατευτικά αντισώματα αντι-γλυκάνης αλλά δεν προκαλεί αντισώματα τα οποία αναστέλλουν την προστατευτική δράση των αντισωμάτων αντι-γλυκάνης. Η γλυκάνη μπορεί να παρουσιάζεται στην επιφάνεια μικροβιακού κυττάρου κατεργασμένου με πρωτεάση ή μπορεί να παρουσιάζεται σαν ένα σύζευγμα πρωτεΐνης-γλυκάνης. Η γλυκάνη μπορεί να αντικατασταθεί από έναν μιμότοπο γλυκάνης, ένα πεπτιδομιμητικό μιμότοπου γλυκάνης, η νουκλεϊνικό οξύ που κωδικεύει έναν μιμότοπο. Τα αντισώματα αντιγλυκάνης δείχνουν μικροβιοκτόνο ενεργότητα ευρέους φάσματος. Προτιμούνται οι β-γλυκάνες, ιδιαίτερα αυτές που περιέχουν μία ή περισσότερες β-1,6 συνδέσεις.
CY20081100809T 2002-05-15 2008-07-31 Αντι-μυκητικα εμβολια βασιζομενα σε βητα-γλυκανη CY1108234T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0211118.5A GB0211118D0 (en) 2002-05-15 2002-05-15 Vaccines
EP03730424A EP1506009B1 (en) 2002-05-15 2003-05-15 Beta-glucan-based anti-fungal vaccines

Publications (1)

Publication Number Publication Date
CY1108234T1 true CY1108234T1 (el) 2014-02-12

Family

ID=9936711

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100809T CY1108234T1 (el) 2002-05-15 2008-07-31 Αντι-μυκητικα εμβολια βασιζομενα σε βητα-γλυκανη

Country Status (15)

Country Link
US (4) US20050208079A1 (el)
EP (2) EP1506009B1 (el)
JP (3) JP5110767B2 (el)
AT (2) ATE395080T1 (el)
AU (1) AU2003241104A1 (el)
CA (2) CA2830619A1 (el)
CY (1) CY1108234T1 (el)
DE (2) DE60320979D1 (el)
DK (1) DK1506009T3 (el)
ES (1) ES2306871T3 (el)
GB (1) GB0211118D0 (el)
HK (2) HK1069125A1 (el)
PT (1) PT1506009E (el)
SI (1) SI1506009T1 (el)
WO (1) WO2003097091A2 (el)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP1733231B1 (en) * 2004-04-05 2011-05-04 Université Bordeaux 2 Peptides and peptidomimetics binding to cd23
GB0420466D0 (en) * 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
KR20130122810A (ko) 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
EP1984004A4 (en) * 2006-01-17 2010-03-03 Sloan Kettering Inst Cancer THE THERAPY REINFORCING GLUCAN
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20070253985A1 (en) * 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
AU2013203785B2 (en) * 2006-11-06 2016-11-17 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
ES2397186T3 (es) 2006-11-06 2013-03-05 Whitehead Institute Composiciones inmunomoduladoras y métodos para su uso
JP4687644B2 (ja) 2006-12-22 2011-05-25 富士ゼロックス株式会社 画像処理装置、画像読取装置及び画像形成装置
ES2599908T3 (es) * 2007-11-26 2017-02-06 Glaxosmithkline Biologicals Sa Glucanos beta-1,3-enlazados conjugados
US20100266626A1 (en) * 2007-11-26 2010-10-21 Francesco Berti Adjuvanted glucans
CA2760044A1 (en) * 2008-04-29 2009-11-05 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
US20110236489A1 (en) 2008-09-18 2011-09-29 Novartis Ag Vaccine adjuvant combinations
NL1036661C2 (en) 2009-03-04 2010-09-07 Serrix B V Anti-fungal compounds & compositions.
BRPI1008984A2 (pt) * 2009-03-10 2016-07-05 Palmed Teva Ltd novas e distintas variedades de cogumelos basidiomycotas superiores, biomassa de cogumelo, biomassa micelial, extrato de um cogumelo, cultura micelial submersa pura de coprinus comatus, cultura micelial submersa pura de tremella mesentérica, b-glucano de baixo peso molecular solúvel em água 3,4 b-glucano linear insolúvel em água obtiodo a partir de tremella mesentérica, glucuronixilomanano obtido a partir de tremella mesentérica, suplemento alimentar, comida para animais, composição farmacêutica e composição agrícola.
WO2011024071A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
DK2459216T3 (da) 2009-09-02 2013-12-09 Novartis Ag Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
SG185485A1 (en) * 2010-05-14 2012-12-28 Alltech Inc Yeast cell wall components and detection thereof
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
ES2630029T3 (es) 2010-12-14 2017-08-17 Glaxosmithkline Biologicals Sa Análisis de citometría de flujo de materiales adsorbidos en sales metálicas
BR112013022397A2 (pt) 2011-03-02 2017-09-26 Derek O’Hagan vacinas combinadas com doses menores de antígeno e/ou adjuvante
EP2729178A1 (en) 2011-07-08 2014-05-14 Novartis AG Tyrosine ligation process
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
SI2822947T1 (sl) 2012-03-07 2016-10-28 Glaxosmithkline Biologicals S.A. Argininske soli TLR7 agonista
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
JP6345603B2 (ja) 2012-03-08 2018-06-20 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
EP2854530B1 (en) * 2012-04-30 2018-01-03 Biothera, Inc. Compositions for beta-glucan immunotherapy
WO2014118305A1 (en) 2013-02-01 2014-08-07 Novartis Ag Intradermal delivery of immunological compositions comprising toll-like receptor agonists
CN103083663B (zh) * 2013-02-04 2014-12-10 江苏省农业科学院 一种免疫增强剂、灭活疫苗及其制备方法
WO2014158963A1 (en) 2013-03-12 2014-10-02 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides
ES2756526T3 (es) 2013-07-11 2020-04-27 Novartis Ag Modificaciones de proteínas quimioenzimáticas específicas para lisina utilizando transglutaminasa microbiana
CN106170698A (zh) * 2013-12-05 2016-11-30 生物治疗公司 β‑葡聚糖测定方法
CN104771498A (zh) * 2015-03-13 2015-07-15 臧海阳 一种治疗热毒蕴结型痄腮的中药组合物
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
WO2019141774A1 (en) * 2018-01-19 2019-07-25 Miltenyi Biotec Gmbh Regulatory t cell expressing a chimeric antigen receptor
US11701417B2 (en) * 2019-03-27 2023-07-18 West Virginia University Vaccine formulation to protect against pertussis
WO2023002252A1 (en) 2021-07-21 2023-01-26 Bioatlantis Limited Composition comprising beta-glucans and alpha-fucans for improving gut health and animal performance and methods of making the same
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
WO2023161527A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466289B (sv) * 1984-09-19 1992-01-27 James Hoffman Makrofagstimulerande komposition jaemte foerfarande foer dess framstaellning
JPS6383012A (ja) * 1986-09-26 1988-04-13 Nonogawa Shoji:Kk 化粧料
CA2066172A1 (en) * 1989-09-08 1991-03-09 Alpha Beta Technology, Inc. Method for producing soluble glucans
EP0471954A3 (en) * 1990-08-13 1993-03-03 American Cyanamid Company Immunogenic conjugates of nontoxic oligosaccharide derived from bordetella pertussis lipooligosaccharide
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
DE69434079T2 (de) * 1993-03-05 2005-02-24 Wyeth Holdings Corp. Plasmid zur Herstellung von CRM-Protein und Diphtherie-Toxin
CN1094288A (zh) * 1993-04-23 1994-11-02 福建省微生物研究所 利用红色诺卡氏菌制造细胞壁骨架粉末的方法
NO300692B1 (no) 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
US6309642B1 (en) * 1997-04-28 2001-10-30 The Research And Development Institute, Inc. Peptides which mimic candida carbohydrate epitopes and their use in a vaccine
AUPN166195A0 (en) 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
JPH09309842A (ja) * 1996-05-20 1997-12-02 Kureha Chem Ind Co Ltd 新規な生理活性物質、その製造方法及び医薬組成物
US6573245B1 (en) * 1998-04-28 2003-06-03 Galenica Pharmaceuticals, Inc. Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
JP4230635B2 (ja) 2000-02-29 2009-02-25 富士フイルム株式会社 デジタルカメラ

Also Published As

Publication number Publication date
US20070141088A1 (en) 2007-06-21
CA2485847C (en) 2013-12-31
US8679506B2 (en) 2014-03-25
DE60320979D1 (de) 2008-06-26
JP5684758B2 (ja) 2015-03-18
US20050208079A1 (en) 2005-09-22
SI1506009T1 (sl) 2008-10-31
JP5110767B2 (ja) 2012-12-26
EP1506009A2 (en) 2005-02-16
ATE395080T1 (de) 2008-05-15
US7824688B2 (en) 2010-11-02
US20110059120A1 (en) 2011-03-10
HK1114335A1 (en) 2008-10-31
HK1069125A1 (en) 2005-05-13
EP1891970B1 (en) 2011-02-09
EP1506009B1 (en) 2008-05-14
GB0211118D0 (en) 2002-06-26
ES2306871T3 (es) 2008-11-16
DK1506009T3 (da) 2008-09-01
PT1506009E (pt) 2008-08-14
WO2003097091A3 (en) 2004-03-04
US20130171187A1 (en) 2013-07-04
ATE497781T1 (de) 2011-02-15
EP1891970A1 (en) 2008-02-27
DE60336027D1 (de) 2011-03-24
JP2012224636A (ja) 2012-11-15
WO2003097091A2 (en) 2003-11-27
CA2830619A1 (en) 2003-11-27
US8398990B2 (en) 2013-03-19
CA2485847A1 (en) 2003-11-27
AU2003241104A1 (en) 2003-12-02
JP2010131017A (ja) 2010-06-17
JP2005535298A (ja) 2005-11-24

Similar Documents

Publication Publication Date Title
CY1108234T1 (el) Αντι-μυκητικα εμβολια βασιζομενα σε βητα-γλυκανη
NZ511201A (en) Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
EP2289549A3 (en) Immunoconjugates for treating cancer
DE60019693D1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
TW200514580A (en) Adhesive preparations
MX368377B (es) Combinacion de brimonidina y timolol para uso oftalmico, topico.
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
WO2003082926A3 (en) Antimicrobial polymer conjugates
EA200501828A1 (ru) Тканепротекторные цитокины с увеличенным терапевтическим окном для защиты, восстановления и стимулирования реагирующих клеток, тканей и органов
EP4295917A3 (en) Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
TW200602295A (en) Organic compounds
ATE260559T1 (de) Sordarinderivate
WO2001070184A3 (en) A composition containing monoterpenes for topical oral administration
WO2002055022A3 (en) Active metabolite of antifungal compound
WO2003000174A3 (en) Compositions and methods for intracellular delivery
WO2003007878A3 (en) Antifungal agents of sordarin derivatives
NZ584942A (en) Injectable meclizine formulations and methods comprising a molar excess of a modified cyclodextrin
ID26929A (id) Fungisida
ATE238050T1 (de) 4-cyano-4-deformylsordarizin-derivate
WO2004052331A3 (fr) Utilisation d'un extrait de miellat de coton comme ingredient acitif
WO2004052282A3 (en) Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents
EP0943339A3 (en) Method of preventing allograft rejection
EP1007031A4 (en) 4-CYANO-4-DEFORMYLSORDARINE DERIVATIVES
HK1064955A1 (en) Composition comprising demethylcantharidin in combination with platinum-containing anticancer agentsand use thereof